Get the Stockscreener App
0.201
3.13%
-0.0065
After Hours:
.21
0.009
+4.48%
Endra Life Sciences Inc stock is traded at $0.201, with a volume of 917.02K.
It is down -3.13% in the last 24 hours and down -47.48% over the past month.
ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI but at 1/50th the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.
See More
Previous Close:
$0.2075
Open:
$0.2094
24h Volume:
917.02K
Relative Volume:
0.27
Market Cap:
$3.65M
Revenue:
-
Net Income/Loss:
$-10.06M
P/E Ratio:
-0.0605
EPS:
-3.32
Net Cash Flow:
$-9.58M
1W Performance:
-6.64%
1M Performance:
-47.48%
6M Performance:
-99.31%
1Y Performance:
-99.64%
1-Day Range:
$0.1964
$0.2094
1-Week Range:
$0.1964
$0.2258
52-Week Range:
$0.19
$139.50
Endra Life Sciences Inc Stock (NDRA) Company Profile
Name
Endra Life Sciences Inc
Sector
Industry
Phone
734-335-0468
Address
3600 GREEN COURT, ANN ARBOR, MI
Endra Life Sciences Inc Stock (NDRA) Latest News
ENDRA Life Sciences Inc (NDRA) is a good investment, but the stock may be overvalued - US Post News
The time has not yet come to remove your chips from the table: ENDRA Life Sciences Inc (NDRA) - SETE News
Benjamin F. Edwards & Company Inc. Purchases 693 Shares of Ingredion Incorporated (NYSE:INGR) - Defense World
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.36% - MSN
Ababaka ku kakiiko k’ebyobulamu barambudde fakitole ekola eddagala - NTV Uganda
ENDRA Life Sciences Inc: Analyzing NDRA Stock Trends - The InvestChronicle
INDIGO Biosciences Launches New Cell-Based Luciferase Reporter Assay for the Human Melanocortin 2 Receptor - EIN News
A closer look at ENDRA Life Sciences Inc (NDRA) is warranted - US Post News
Investor’s Delight: ENDRA Life Sciences Inc (NDRA) Closes Weak at 0.20, Down -6.77 - The Dwinnex
Insider Buys Additional ₹33m In NRB Bearings Stock - Simply Wall St
Balakrishna on VenkyAnil3 sets: Iddharu Sankranthike Vasthunnaru - TeluguOne News
Renaissance Technologies LLC Has $37.73 Million Stock Holdings in InMode Ltd. (NASDAQ:INMD) - Defense World
10:1 Stock Split Record Date Today: Multibagger Penny Stock Under Rs 10 Hit Upper Circuit & 52-Week High On September 19 - Dalal Street Investment Journal
ENDRA Life Sciences Inc (NDRA) can make a big difference with a little luck - SETE News
Ratio Examination: ENDRA Life Sciences Inc (NDRA)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
How did ENDRA Life Sciences Inc (NDRA) fare last session? - US Post News
NDRA’s Financial Health: Exploring ENDRA Life Sciences Inc’s Debt-to-Equity Ratio of 1.79 - The InvestChronicle
Closing Figures Unveiled: ENDRA Life Sciences Inc (NDRA) Drop -2.40, Closes at 0.24 - The Dwinnex
Check out these key findings about ENDRA Life Sciences Inc (NDRA) - SETE News
NDRA’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - The InvestChronicle
ENDRA Life Sciences (NASDAQ:NDRA) Shares Down 7.7% - Defense World
ENDRA Life Sciences Inc [NDRA] Investment Guide: What You Need to Know - Knox Daily
CEO Vacancy Triggers Management Shuffle At ENDRA Life Sciences - MPO-mag
ENDRA Life Sciences Inc (NDRA) deserves closer scrutiny - US Post News
Investor’s Toolkit: Key Ratios for Assessing ENDRA Life Sciences Inc (NDRA)’s Performance - The Dwinnex
SEC Form PRE 14A filed by ENDRA Life Sciences Inc. - Quantisnow
Prepare Yourself for Liftoff: ENDRA Life Sciences Inc (NDRA) - SETE News
ENDRA Life Sciences stock hits 52-week low at $0.37 - Investing.com
Anchoring Your Portfolio: Is NDRA Stock a Safe Harbor? - The InvestChronicle
Daily Market Movement: ENDRA Life Sciences Inc (NDRA) Sees a -8.88 Decrease, Closing at 0.38 - The Dwinnex
ENDRA Life Sciences Inc (NASDAQ: NDRA): Getting A Free Pass? - Stocks Register
United States shares higher at close of trade; Dow Jones Industrial Average up 0.14% - MSN
Data I/O And 2 Other Stocks Under $5 Executives Are Buying - Benzinga
UBS Group AG buys $2,051 of ENDRA Life Sciences shares - Investing.com India
UBS Group AG buys $2,051 of ENDRA Life Sciences shares - Investing.com
ENDRA Life Sciences Strives for Nasdaq Compliance - TipRanks
Nasdaq grants ENDRA extension to meet listing standards - Investing.com
Nasdaq grants ENDRA extension to meet listing standards By Investing.com - Investing.com UK
ENDRA Life Sciences Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirements - StockTitan
Post-Trade Analysis: ENDRA Life Sciences Inc (NDRA) Climbs 62.42, Closing at 0.64 - The Dwinnex
Endra Life Sciences granted extension to regain Nasdaq compliance - TipRanks
ENDRA Life Sciences Inc (NDRA) Stock: The Story of a 52-Week Stock Range - The InvestChronicle
What to expect from ENDRA Life Sciences Inc’s (NDRA) current quarter earnings? - US Post News
ENDRA Life Sciences Inc (NDRA) Q2 2024 Earnings Call Transcript Highlights: Strategic Shifts and Financial Updates - GuruFocus.com
ENDRA Life Sciences Inc (NDRA) Q2 2024 Earnings Call Transcript Highlights: Strategic Shifts … - Stockxpo
Q2 2024 ENDRA Life Sciences Inc Earnings Call Transcript - Stockxpo
ENDRA Life Sciences Discusses Quarterly Results in Call - TipRanks
Earnings call: ENDRA Life Sciences reports Q2 2024 results, strategic shifts - Investing.com
Earnings call: ENDRA Life Sciences reports Q2 2024 results, strategic shifts - Investing.com UK
ENDRA Life Sciences Reports Second Quarter 2024 Financial Results and Provides a Business Update - wallstreet:online
ENDRA Life Sciences stock hits 52-week low at $0.43 amid steep decline - Investing.com Australia
Endra Life Sciences Inc Stock (NDRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.62%
1.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):